Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
Thirty patients older than 65 years of age with acute nonlymphocytic leukemia were treated with low-dose cytosine arabinoside (10 mg/m2 subcutaneously every 12 hours for 15 to 21 days). Fifteen achieved complete remission and five had partial remission. Treatment was more effective when initial bone marrow cellularity was low (P = 0.007). Four of six patients with secondary leukemia entered complete or partial remission. Therapy was well tolerated with reduced myelosuppression and few number of early deaths. Sixteen patients followed the whole treatment as outpatients. Six of 12 patients who achieved complete remission showed no evidence of post-therapeutic bone marrow aplasia. These data are consistent with the view that low-dose cytosine arabinoside acts on leukemic cells as a differentiating agent.
D000208:Acute Disease; D000368:Aged; D000553:Ambulatory Care; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007279:Injections, Subcutaneous; D007938:Leukemia / Q000188:drug therapy* / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D012008:Recurrence
D003561:Cytarabine